Followers | 44 |
Posts | 1911 |
Boards Moderated | 0 |
Alias Born | 04/09/2016 |
Monday, December 26, 2016 8:50:10 PM
Taken from the $ETST patent:
CLAIMS(30)
CLAIMS What is claimed is:
1. A pharmaceutical composition for use in the treatment of cancer, comprising:
cannabidiol (CBD); and
one or more compounds selected from the group consisting of D-limonene, astaxanthin, malunggay, euphorbia hirta, pao pereira extract, copaiba and ampalaya.
2. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is suitable for oral, parenteral, or topical administration.
4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises D-limonene.
5. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises astaxanthin.
6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is used in a cancer treatment that comprises one or more other cancer treatment methods.
7. The pharmaceutical composition of claim 6, wherein the one or more other cancer treatment methods comprise laser photothermal therapy.
8. A pharmaceutical composition for use in the treatment of cancer, comprising:
hemp oil enriched with one or more compounds selected from the group consisting of cannabidiol (CBD), D-limonene, astaxanthin, malunggay, euphorbia hirta, pao pereira extract, copaiba and ampalaya.
9. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition comprises CBD.
10. The pharmaceutical composition of claim 9, further comprising a pharmaceutically acceptable excipient.
1 1. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is suitable for oral, parenteral, or topical administration.
12. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition further comprises D-limonene.
13. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition further comprises astaxanthin.
14. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is used in a cancer treatment that comprises one or more other cancer treatment methods.
15. The pharmaceutical composition of claim 14, wherein the one or more other cancer treatment methods comprise laser photothermal therapy.
16. A method of treating breast cancer, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 1.
17. A method of treating breast cancer, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 4.
18. A method of treating breast cancer, comprising: administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 5.
19. A method of treating breast cancer, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 8.
20. A method of treating breast cancer, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 9.
21. A method of modulating the immune system, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 1.
22. A method of modulating the immune system, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 4.
23. A method of modulating the immune system, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 5.
24. A method of modulating the immune system, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 8.
25. A method of modulating the immune system, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 9.
26. A method of providing neuroprotection against reactive oxygen species and lipid peroxidation, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 1.
27. A method of providing neuroprotection against reactive oxygen species and lipid peroxidation, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 4.
28. A method of providing neuroprotection against reactive oxygen species and lipid peroxidation, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 5.
29. A method of providing neuroprotection against reactive oxygen species and lipid peroxidation, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 8.
30. A method of providing neuroprotection against reactive oxygen species and lipid peroxidation, comprising:
administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 9.
Recent ETST News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 05:24:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 10:44:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 10:04:15 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/29/2024 08:05:49 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2024 12:55:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 11:04:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 06:30:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 12:06:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 10:10:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 12:28:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 03:10:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 06:23:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 08:21:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 12:52:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:20:11 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 02/27/2024 01:30:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 02:05:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 05:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:59:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/24/2023 11:01:45 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM